TAL1 (G116) polyclonal, anti-human, mouse
€305.00
In stock
SKU
BS3772
Background:
Activation of TAL1 characterizes up to 60% of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors.
Alternative Name:
T-cell acute lymphocytic leukemia protein 1, TAL-1, Class A basic helix-loop-helix protein 17, bHLHa17, Stem cell protein, T-cell leukemia/lymphoma protein 5, TAL1, BHLHA17, SCL, TCL5
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: TAL1 (G116) polyclonal antibody detects endogenous levels of TAL1 protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 80-130 of Human TAL1.
MW: ~ 45 kDa
Swis Prot.: P17542
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
Activation of TAL1 characterizes up to 60% of cases of human T cell acute lymphoblastic leukemia, making it the most frequent gain-of-function mutation observed in this disorder. TAL1 (also designated SCL) is a serine phosphoprotein and basic helix-loop-helix transcription factor known to regulate embryonic hematopoiesis. This transcription factor binds as a heterodimer with E2A and HEB/HTF4 to a nucleotide sequence motif termed the E-box. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of TAL1 and the catalytic subunit of casein kinase IIalpha, a serine/ threonine protein kinase known to modulate the activity of other bHLH transcription factors.
Alternative Name:
T-cell acute lymphocytic leukemia protein 1, TAL-1, Class A basic helix-loop-helix protein 17, bHLHa17, Stem cell protein, T-cell leukemia/lymphoma protein 5, TAL1, BHLHA17, SCL, TCL5
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: TAL1 (G116) polyclonal antibody detects endogenous levels of TAL1 protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 80-130 of Human TAL1.
MW: ~ 45 kDa
Swis Prot.: P17542
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review